Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | PDE2A | O00408 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23891920 | 1.00 | SLC2A1 (0.47) | SLC2A1PDE2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL1727664 | 1.00 | SLC2A1 (0.47) | SLC2A1PDE2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL3602797 | 0.89 | PDE2A (0.43) | SLC2A1PDE2AGRM8GRM4TACR1 | |
| SCHEMBL3595268 | 0.89 | PDE2A (0.43) | SLC2A1PDE2AGRM8GRM4TACR1 | |
| SCHEMBL906156 | 0.89 | PDE2A (0.43) | SLC2A1PDE2AGRM8GRM4TACR1 | |
| SCHEMBL9350707 | 0.84 | SLC2A1 (0.59) | SLC2A1CA2CYP1A2CYP2C19 | |
| SCHEMBL9950997 | 0.84 | KIF11 (0.46) | PDE2A | |
| SCHEMBL27407732 | 0.84 | SLC2A1 (0.49) | SLC2A1LMNACA2TSHR | |
| SCHEMBL1727790 | 0.82 | TACR1 (0.43) | SLC2A1CA2EPHX1TACR1CYP3A4 | |
| SCHEMBL1727512 | 0.82 | TACR1 (0.43) | SLC2A1CA2EPHX1TACR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530562-B1 | OPTICALLY ACTIVE 1-(FLUORO-,TRIFLUOROMETHYL-OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVES AND PROCESS FOR PRODUCING SAME | CENTRAL GLASS CO LTD (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-7728022-B2 | (3-phenyl-1-{1-[4-(trifluoromethyl)phenyl]butyl}-4,5,6,7-tetrahydro-1H-indol-7-yl)acetic acid, used for treating diseases associated with the deposition of beta -amyloid peptide in the brain | MERCK SHARP & DOHME LTD. (GB) | 2010-06-01 | — | — | US | disclosed |
| US-7728022-B2 | (3-phenyl-1-{1-[4-(trifluoromethyl)phenyl]butyl}-4,5,6,7-tetrahydro-1H-indol-7-yl)acetic acid, used for treating diseases associated with the deposition of beta -amyloid peptide in the brain | MERCK SHARP & DOHME LTD. (GB) | 2010-06-01 | — | — | US | disclosed |
| US-7728022-B2 | (3-phenyl-1-{1-[4-(trifluoromethyl)phenyl]butyl}-4,5,6,7-tetrahydro-1H-indol-7-yl)acetic acid, used for treating diseases associated with the deposition of beta -amyloid peptide in the brain | MERCK SHARP & DOHME LTD. (GB) | 2010-06-01 | — | — | US | disclosed |
| EP-1748982-B1 | (4, 5, 6, 7-TETRAHYDRO-1-H-INDOL-7-YL) ACETIC ACID DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2009-07-29 | — | — | EP | disclosed |
| EP-1748982-B1 | (4, 5, 6, 7-TETRAHYDRO-1-H-INDOL-7-YL) ACETIC ACID DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-7368609-B2 | Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20070232678-A1 | (4, 5, 6, 7-Tetrahydro-1-H-Indol-7-Yl) Acetic Acid Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232678-A1 | (4, 5, 6, 7-Tetrahydro-1-H-Indol-7-Yl) Acetic Acid Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232678-A1 | (4, 5, 6, 7-Tetrahydro-1-H-Indol-7-Yl) Acetic Acid Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070142670-A1 | Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same | CENTRAL GLASS CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-7186865-B2 | Reacting optically active secondary amine with alkylation agent in presence of a base, thereby converting the secondary amine into an optically active tertiary amine and subjecting the tertiary amine to hydrogenolysis, producing the N-monoalkyl derivative; intermediates for drugs, agriculture | CENTRAL GLASS COMPANY, LIMITED (JP) | 2007-03-06 | — | — | US | disclosed |
| WO-2005108362-A1 | (4, 5, 6, 7-TETRAHYDRO-1-H-INDOL-7-YL) ACETIC ACID DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2005-11-17 | — | — | WO | disclosed |
| US-20040235961-A1 | Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232678-A1 | (4, 5, 6, 7-Tetrahydro-1-H-Indol-7-Yl) Acetic Acid Derivatives for Treatment of Alzheimer's Disease | APP, BACE1, CHAT | SLC2A1 2532/4885PDE2A 1534/4885SMN1; SMN2 1945/4885 |
| US-20040235961-A1 | Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same | NAT1, PNMT, AFF1 | SLC2A1 4519/4885PDE2A 1807/4885SMN1; SMN2 3894/4885 |
| US-20070142670-A1 | Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same | NAT1, AFF1, PNMT | SLC2A1 4567/4885PDE2A 1623/4885SMN1; SMN2 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.